Drugs / TTK
last change Apr 2009 re-read 2 minutes ago

TTK

Peptide

Developed for
esophageal cancer
Investigated by
Human Genome Center, Institute of Medical Science, University of Tokyo · Tokyo University

Trials 1 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00681330 May 2008 → Apr 2009 esophageal cancer Tokyo University Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TTK ClinicalTrials.gov intervention name — accepted as the source's own label NCT00681330
Modality Peptide “TTK peptide (1mg)” NCT00681330